Dual HER2/PIK3CA targeting overcomes single-agent acquired resistance in HER2-amplified uterine serous carcinoma cell lines in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 14, Issue 11, 2015, Pages 2519-2526

  Lopez, Salvatore ^a,b   Cocco, Emiliano ^b   Black, Jonathan ^b   Bellone, Stefania ^b   Bonazzoli, Elena ^b   Predolini, Federica ^b   Ferrari, Francesca ^b   Schwab, Carlton L ^b   English, Diana P ^b   Ratner, Elena ^b   Silasi, Dan Arin ^b   Azodi, Masoud ^b   Schwartz, Peter E ^b   Terranova, Corrado ^a   Angioli, Roberto ^a   Santin, Alessandro D ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NERATINIB; PEPTIDES AND PROTEINS BY PEPTIDE STRUCTURE; PROTEIN PIK3CA; TASELISIB; UNCLASSIFIED DRUG; 2-(3-(2-(1-ISOPROPYL-3-METHYL-1H-1,2-4-TRIAZOL-5-YL)-5,6-DIHYDROBENZO(F)IMIDAZO(1,2-D)(1,4)OXAZEPIN-9-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPANAMIDE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; OXAZEPINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARCINOMA CELL LINE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; DRUG TARGETING; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; FLOW CYTOMETRY; GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PIK3CA GENE; PRIORITY JOURNAL; TUMOR XENOGRAFT; UTERINE SEROUS CARCINOMA; UTERUS CARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL SURVIVAL; CYSTADENOCARCINOMA, SEROUS; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION; SCID MOUSE; TUMOR CELL LINE; UTERINE NEOPLASMS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYSTADENOCARCINOMA, SEROUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; GENE AMPLIFICATION; HUMANS; IMIDAZOLES; IMMUNOBLOTTING; MICE, SCID; MUTATION; OXAZEPINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; QUINOLINES; RECEPTOR, ERBB-2; UTERINE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958212984     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0383     Document Type: Article

References (47)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Cancer Genome Atlas Research N Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
3. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
4. Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol 2011;54:278-91.
5. Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol 2010;22:21-9.
6. Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994;54:264-8.
7. Yarden Y, SliwkowskiMX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
8. Burstein HJ. The distinctive nature of HER2-positive breast cancers.NEngl J Med 2005;353:1652-4.
9. Geng Y, Chen X, Qiu J, Zhou Y, Wang J, Liu L, et al. Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer. Int J Clin Oncol 2014;19:303-11.
10. Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med 2014;138:343-50.
11. Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol 2013;26:1605-12.
12. Santin AD, Bellone S, Van Stedum S, BushenW, PalmieriM, Siegel ER, et al. Amplification of c-erbB2 oncogene: amajor prognostic indicator in uterine serous papillary carcinoma. Cancer 2005;104:1391-7.
13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
14. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
15. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7:606-19.
16. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
17. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
18. Salvesen HB, Carter SL,Mannelqvist M, Dutt A,Getz G, Stefansson IM, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 2009;106:4834-9.
19. Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genomewide analyses. J Natl Cancer Inst 2012;104:1503-13.
20. Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A 2013;110:2916-21.
21. Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012;44:1310-5.
22. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-65.
23. Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, et al. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol 2014;135:142-8.
24. Wissner A, Mansour TS. The development of HKI-272 and related compounds for the treatment of cancer. Arch der Pharm 2008;341:465-77.
25. Kosaka T, Yamaki E, Mogi A, Kuwano H.Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011;2011:165214.
26. Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaquiere N, Bradley E, et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1Hpyrazol-1-yl}-2-methylpropanamide (GDC-0032): a beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem 2013;56:4597-610.
27. Lopez S, Schwab CL, Cocco E, Bellone S, Bonazzoli E, English DP, et al. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CAmutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol 2014;135:312-7.
28. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
29. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 2005;102:802-7.
30. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81.
31. English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther 2013;17:85-99.
32. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
33. Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, et al. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. Br J Cancer 2014; 111:1750-6.
34. Tan J, Yu Q. Molecular mechanisms of tumor resistance to PI3K-mTORtargeted therapy. Chin J Cancer 2013;32:376-9.
35. Pavlidou A, Vlahos NF. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer. ScientificWorldJournal 2014;2014:709736.
36. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/ Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008;11:32-50.
37. Martin-Liberal J, Larkin J. Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Future Oncol 2015;11:579-89.
38. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
39. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-9.
40. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014;4:80-93.
41. Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 2010;9:75.
42. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010;21:255-62.
43. PIK3CA mutation predicts resistance to breast cancer therapy. Cancer Discov 2014;4:OF3.
44. Berns K, Horlings HM, Hennessy BT,Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402.
45. O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, et al. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res 2014; 20:3507-20.
46. Garcia-Garcia C, Ibrahim YH, Serra V, Calvo MT, GuzmanM,Grueso J, et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 2012;18:2603-12.
47. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011; 30:2547-57.